VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM

Ontario Industry Updates
Written By Doriane Rey

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, recently announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence.

Doriane Rey
Previous

Providence Therapeutics Holdings Inc. of Canada and Biological E. Limited of India announce the execution of a term sheet for the licensing and collaboration of mRNA vaccine
Next

Fusion Pharmaceuticals Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility